65.00
-5.50
(-7.80%)
As of 8:00:43 AM GMT+2. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 9 | 8 | 9 | 9 |
| Avg. Estimate | 958.18M | 1.06B | 3.94B | 4.19B |
| Low Estimate | 947M | 1.04B | 3.88B | 4.08B |
| High Estimate | 969M | 1.07B | 4.08B | 4.39B |
| Year Ago Sales | 933.49M | 1.02B | 3.72B | 3.94B |
| Sales Growth (year/est) | 2.64% | 4.51% | 5.98% | 6.50% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| PK2.F | -- | -- | -- | -- |
| S&P 500 | 6.55% | 6.50% | 9.70% | 14.29% |
Upgrades & Downgrades
| Downgrade | Baird: Outperform to Neutral | 4/4/2025 |
| Maintains | Truist Securities: Buy to Buy | 2/10/2025 |
| Maintains | Benchmark: Buy to Buy | 2/7/2025 |
| Maintains | Raymond James: Outperform to Outperform | 2/7/2025 |
| Maintains | Keybanc: Overweight to Overweight | 2/7/2025 |
| Maintains | Truist Securities: Buy to Buy | 1/7/2025 |